OncoTherics Poland Sp. z o.o.

OncoTherics, a biopharmaceutical startup based in Kraków, specializes in developing hypoxia-activated prodrugs (HAPs) for treating a wide range of cancers. Its flagship molecule OCT1002 uses patented technology enabling faster-than-usual progression through clinical trials. A spin-out from BioStatus, the company combines advanced oncological research with a highly specialized team of ~6 people.